News
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...
Super Micro, AMD, and Snap stocks tumbled after quarterly earnings reports. Arista and Disney stocks were rising.
Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback